Shelby Umland, Ph.D., joined Hurley Consulting in 2007 as Executive Director, Nonclinical Pharmacology. She has over twenty-five years experience in the pharmaceutical industry. Her expertise is in respiratory, inflammatory and auto immune diseases. She has been team leader for multiple drug discovery programs and has prepared many nonclinical sections of NDAs, INDs and Investigator Brochures.

At Hurley Consulting, Dr. Umland is responsible for nonclinical research activities. She directs and manages scientists involved in the interpretation and evaluation of nonclinical research data. Dr. Umland ensures correct and appropriate analysis and interpretation of nonclinical results and project appropriate data review. She oversees the preparation of nonclinical summary documents and study reports and provides input on nonclinical study design. Dr. Umland participates in the development of project timelines, prioritizes and delegates tasks to project teams, and provides status updates as projects progress.

Before joining Hurley Consulting, Dr. Umland was Senior Fellow, Department of Inflammation at Schering Plough Research Institute. In this capacity, she supervised scientists within the department for multiple drug discovery programs for inflammatory (IBD, MS, RA, psoriasis) and allergic (asthma, rhinitis) disease indications. In addition, she provided management, strategic direction and experimental support for discovery programs involving diverse molecular targets including cytokine inhibitors and biologics, GPCR agonists and antagonists, ion channels and proteases. She contributed to the collaboration between Schering Plough Research Institute and Genome Therapeutics Corporation in asthma gene discovery, resulting in identification of ADAM33.

Dr. Umland holds a doctoral degree in immunology from Rutgers University, a master’s degree from Seton Hall University and a bachelor’s degree in biology from Gettysburg College. She has authored or co-authored over 50 journal articles and holds two patents.